In a report released today, George Farmer from Scotiabank maintained a Buy rating on Tempest Therapeutics (TPST – Research Report), with a price target of $13.00. The company’s shares closed yesterday at $3.47.
According to TipRanks, Farmer is a 4-star analyst with an average return of 16.0% and a 55.13% success rate. Farmer covers the Healthcare sector, focusing on stocks such as Legend Biotech, Tempest Therapeutics, and SAGE Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Tempest Therapeutics with a $22.67 average price target, implying a 553.31% upside from current levels. In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $47.00 price target.
TPST market cap is currently $77.09M and has a P/E ratio of -1.81.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Tempest Therapeutics (TPST) Company Description:
Tempest Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapeutics to treat cancer.
Read More on TPST:
- Tempest Reports First Quarter 2024 Financial Results and Provides Business Update
- Is TPST a Buy, Before Earnings?
- Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Largest borrow rate increases among liquid names
- Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting
